

Eohilia is hard to find due to specialty pharmacy distribution, insurance barriers, and limited availability. Learn why and what you can do about it.
If you or someone you love has been prescribed Eohilia (Budesonide oral suspension) for eosinophilic esophagitis (EoE), you may have already discovered something frustrating: finding it in stock is not easy. You're not alone. Many patients across the country are struggling to get their hands on this medication.
Eohilia was approved by the FDA in February 2024 as the first oral treatment specifically designed for EoE in patients 11 years and older. It's made by Takeda Pharmaceuticals and is a 12-week course of treatment. While it was a breakthrough for the EoE community, getting the prescription filled has been a different story.
Unlike most medications you pick up at your local CVS or Walgreens, Eohilia is distributed through specialty pharmacies. This means your regular pharmacy likely cannot order it or stock it. Specialty pharmacies handle medications that are expensive, require special storage, or treat complex conditions.
Because Eohilia costs around $1,930 or more per 30-day supply without insurance, most retail pharmacies don't carry it. You'll need to work with a specialty pharmacy that has a relationship with Takeda's distribution network.
Even if you find a specialty pharmacy that stocks Eohilia, your insurance company may put up roadblocks. Most health plans require prior authorization before they'll cover Eohilia. Some also require step therapy, meaning you may need to try and fail on other treatments (like proton pump inhibitors or off-label swallowed steroids) before your plan will approve Eohilia.
This process can take 1 to 2 weeks — or longer if your first request is denied and you need to appeal. During this time, you're left waiting without your medication.
Eohilia has no generic equivalent. It is the only FDA-approved Budesonide oral suspension formulated specifically for EoE. While doctors have been prescribing compounded budesonide slurries off-label for years, Eohilia is a different product with a specific formulation designed to coat the esophagus.
Because there's no generic competition, there's only one manufacturer and one supply chain. If demand increases or there's any hiccup in production, patients feel it immediately.
Eosinophilic esophagitis affects an estimated 1 in 2,000 people in the United States. While awareness is growing, it's still considered a rare condition. That means pharmacies — even specialty ones — may not prioritize keeping Eohilia in stock compared to higher-volume medications.
This creates a frustrating cycle: fewer pharmacies stock it, which makes it harder to find, which makes demand seem lower, which gives pharmacies less reason to stock it.
Here are some practical steps if you're struggling to find Eohilia:
For more tips, read our guide on how to find Eohilia in stock near you.
As of early 2026, Eohilia is not listed on the FDA's official drug shortage list. However, the limited distribution model means that many patients experience practical shortages — the drug exists, but they can't access it easily. For the latest updates, check our Eohilia shortage update for 2026.
Eohilia is hard to find because of specialty pharmacy distribution, high cost, insurance barriers, and the niche nature of EoE. But there are tools and programs that can help. Stay proactive, work closely with your doctor, and use resources like MedFinder to track availability in your area.
If cost is also a concern, read our post on how to save money on Eohilia in 2026.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.